Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritus in Subjects With Prurigo Nodularis

NCT03816891 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT03816891
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03816891 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritus in Subjects With Prurigo Nodularis
Lead sponsor
Genentech, Inc.
Phase
Phase 2
Overall status
Completed
Start date
March 11, 2019
Completion date
August 24, 2023
Enrollment
240 (actual)
Sites
86

Conditions

As the registry lists them; a condition with its own page is linked.

prurigo nodularis, pruritis